Literature DB >> 16322085

Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.

C Carli1, A G C Ehlin, L Klareskog, S Lindblad, S M Montgomery.   

Abstract

OBJECTIVE: To characterise temporal trends and factors associated with the prescription of disease modifying antirheumatic drugs (DMARDs) at the initial consultation in early rheumatoid arthritis (RA).
METHODS: Data from 2584 patients with early RA at 19 hospitals were extracted from the Swedish Rheumatoid Arthritis Register for the period 1997-2001. Disease characteristics and DMARD prescription at first consultation with the rheumatologist were investigated using cross tabulation and logistic regression.
RESULTS: DMARD prescriptions, particularly for methotrexate, increased from 1997 to 2001 independently of patient characteristics. Stratification by hospital type showed that patients in district hospitals were less likely to be prescribed DMARDs than those in university hospitals (adjusted odds ratio (OR) = 0.53 (95% confidence interval (CI) 0.40 to 0.69), p<0.001), independently of confounding factors. Association of the DAS28 with the likelihood of DMARD prescription was greater among patients attending district hospitals (OR = 1.65 (1.34 to 2.02), p<0.001) than those at university hospitals (OR = 1.23 (1.07 to 1.41), p = 0.003) and county hospitals (OR = 1.34 (1.01 to 1.63), p = 0.003). Interaction testing indicated that the difference was significant (p = 0.007).
CONCLUSIONS: Temporal trends in DMARD prescription indicate an increasingly aggressive approach to disease management among Swedish rheumatologists. However, the association of hospital type with DMARD prescription suggests that the adoption of research findings in clinical care varies considerably.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322085      PMCID: PMC1798265          DOI: 10.1136/ard.2004.027656

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis.

Authors:  J M Albers; L Paimela; P Kurki; K B Eberhardt; P Emery; M A van 't Hof; F H Schreuder; M Leirisalo-Repo; P L van Riel
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

2.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

3.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

4.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Authors:  Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2002-04

5.  Second-line drugs used in recent-onset rheumatoid arthritis in Brittany (France).

Authors:  Alain Saraux; Jean-Marie Berthelot; Gérard Chalès; Henaff Catherine Le; Jean Thorel; Sylvie Hoang; Antoine Martin; Jérĵme Allain; Isabelle Nouy-Trolle; Valérie Devauchelle; Pierre Youinou; Goff Paul Le
Journal:  Joint Bone Spine       Date:  2002-01       Impact factor: 4.929

6.  Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire.

Authors:  C Ekdahl; K Eberhardt; S I Andersson; B Svensson
Journal:  Scand J Rheumatol       Date:  1988       Impact factor: 3.641

7.  Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis.

Authors:  M L Prevoo; P L van Riel; M A van 't Hof; M H van Rijswijk; M A van Leeuwen; H H Kuper; L B van de Putte
Journal:  Br J Rheumatol       Date:  1993-07

8.  Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years.

Authors:  D Aletaha; G Eberl; V P K Nell; K P Machold; J S Smolen
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

9.  What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis?

Authors:  L A Criswell; C J Henke
Journal:  J Rheumatol       Date:  1995-05       Impact factor: 4.666

10.  Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression.

Authors:  A A Stenger; M A Van Leeuwen; P M Houtman; G A Bruyn; F Speerstra; B C Barendsen; E Velthuysen; M H van Rijswijk
Journal:  Br J Rheumatol       Date:  1998-11
View more
  11 in total

1.  Framework for assessing quality of care for inflammatory bowel disease in Sweden.

Authors:  Martin Rejler; Jörgen Tholstrup; Mattias Elg; Anna Spångéus; Boel Andersson Gäre
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

2.  Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study.

Authors:  Iván Ferraz-Amaro; Daniel Seoane-Mato; Fernando Sánchez-Alonso; María A Martín-Martínez
Journal:  Rheumatol Int       Date:  2015-09-24       Impact factor: 2.631

Review 3.  Neutropenia in the Elderly: A Rheumatology Perspective.

Authors:  Su-Ann Yeoh; Christine Fox; Richard Hull
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

4.  The Trends of DMARDS prescribed in Rheumatoid Arthritis Patients in Malaysia.

Authors:  Wahinuddin Sulaiman; Ashraful Toib; Giriyappanavar Chandrashekhar; Anwar Arshad
Journal:  Oman Med J       Date:  2009-10

5.  Time trends in medication use and expenditures in older patients with rheumatoid arthritis.

Authors:  Leslie R Harrold; Daniel Peterson; Ashley J Beard; Jerry H Gurwitz; Becky A Briesacher
Journal:  Am J Med       Date:  2012-06-09       Impact factor: 4.965

Review 6.  Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs.

Authors:  Tuulikki Sokka; Minja Envalds; Theodore Pincus
Journal:  Mod Rheumatol       Date:  2008-04-25       Impact factor: 3.023

7.  Utilization patterns of disease-modifying antirheumatic drugs in elderly rheumatoid arthritis patients.

Authors:  Xue-Mei Jin; Joongyub Lee; Nam-Kyong Choi; Jong-Mi Seong; Ju-Young Shin; Ye-Jee Kim; Mi-Sook Kim; Bo Ram Yang; Byung-Joo Park
Journal:  J Korean Med Sci       Date:  2014-01-28       Impact factor: 2.153

8.  DMARD non-use in low-income, elderly rheumatoid arthritis patients: results of 86 structured interviews.

Authors:  Erika M Brown; Katie L Garneau; Hsun Tsao; Daniel H Solomon
Journal:  Arthritis Res Ther       Date:  2014-01-29       Impact factor: 5.156

9.  Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations.

Authors:  Leslie R Harrold; George W Reed; Joel M Kremer; Jeffrey R Curtis; Daniel H Solomon; Marc C Hochberg; Arthur Kavanaugh; Katherine C Saunders; Ying Shan; Tanya M Spruill; Dimitrios A Pappas; Jeffrey D Greenberg
Journal:  Arthritis Res Ther       Date:  2016-04-26       Impact factor: 5.156

10.  A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference.

Authors:  Harald J Hamre; Van N Pham; Christian Kern; Rolf Rau; Jörn Klasen; Ute Schendel; Lars Gerlach; Attyla Drabik; Ludger Simon
Journal:  Patient Prefer Adherence       Date:  2018-03-16       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.